This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Shire Pharma Canada ULC
Shire Pharma Canada ULC, a subsidiary of Takeda Pharmaceutical Company, is a leading player in the biopharmaceutical industry, headquartered in Canada. Established in 1986, Shire has made significant strides in developing innovative therapies for rare diseases, particularly in the fields of neuroscience, immunology, and genetic disorders. With a strong presence across Canada, Shire is renowned for its core products, including treatments for attention deficit hyperactivity disorder (ADHD) and rare genetic conditions. The company’s commitment to patient-centric solutions and its robust pipeline of unique therapies have solidified its position as a trusted name in the pharmaceutical landscape. Notable achievements include pioneering advancements in enzyme replacement therapies, which have transformed the lives of patients with rare metabolic disorders.
DitchCarbon Score
How does Shire Pharma Canada ULC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shire Pharma Canada ULC's score of 75 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shire Pharma Canada ULC currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family relationship with Takeda Pharmaceutical Company Limited, from which it inherits climate commitments and initiatives. Takeda has set ambitious targets for carbon reduction, which are cascaded down to Shire Pharma Canada ULC. These initiatives include participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which aim to enhance transparency and accountability in climate action. While specific reduction targets for Shire Pharma Canada ULC are not detailed, the overarching commitments from Takeda reflect a strong dedication to sustainability and reducing environmental impact. The company is also involved in initiatives like RE100 and the Climate Pledge, further demonstrating its commitment to addressing climate change. In summary, while Shire Pharma Canada ULC does not have specific emissions data or reduction targets available, it aligns with the climate commitments and strategies of its parent company, Takeda Pharmaceutical Company Limited, to drive sustainability efforts within its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shire Pharma Canada ULC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
